Role of Iron in Neurodegenerative Disorders
暂无分享,去创建一个
[1] Steven M LeVine,et al. Iron deposits in multiple sclerosis and Alzheimer's disease brains , 1997, Brain Research.
[2] Luisa Mola Morales,et al. Serum ferritin deficiency in Huntington's disease patients , 1991, Neuroscience Letters.
[3] J. Østergaard,et al. In vivo Diagnosis of Hollervorden‐Spatz Disease , 1995 .
[4] M. Youdim,et al. Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction. , 1996, European journal of pharmacology.
[5] M. Youdim,et al. Nutritional Iron Deprivation Attenuates Kainate‐Induced Neurotoxicity in Rats: Implications for Involvement of Iron in Neurodegeneration , 2004, Annals of the New York Academy of Sciences.
[6] Raffaella Mariani,et al. MR imaging of cerebral cortical involvement in aceruloplasminemia. , 2005, AJNR. American journal of neuroradiology.
[7] Daniela Berg,et al. Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings , 2001, Journal of Neurology.
[8] E. Kremmer,et al. α-Synuclein accumulation in a case of neurodegeneration with brain iron accumulation type 1 (NBIA-1, formerly Hallervorden-Spatz syndrome) with widespread cortical and brainstem-type Lewy bodies , 2000, Acta Neuropathologica.
[9] Aaron Ciechanover,et al. The Ubiquitin Proteasome System in Neurodegenerative Diseases Sometimes the Chicken, Sometimes the Egg , 2003, Neuron.
[10] T. Meitinger,et al. Genotypic and phenotypic spectrum of PANK2 mutations in patients with neurodegeneration with brain iron accumulation , 2006, Annals of neurology.
[11] B. Ghetti,et al. Neurodegeneration Caused by Proteins with an Aberrant Carboxyl‐Terminus , 2004, Journal of neuropathology and experimental neurology.
[12] Raffaele Lodi,et al. Mitochondrial Dysfunction in Friedreich’s Ataxia , 2001, Neurosignals.
[13] A. Filla,et al. Magnetic resonance imaging in “typical” and “late onset” Friedreich's disease and early onset cerebellar ataxia with retained tendon reflexes , 1995, The Italian Journal of Neurological Sciences.
[14] Mark A. Smith,et al. In Situ Oxidative Catalysis by Neurofibrillary Tangles and Senile Plaques in Alzheimer’s Disease , 2000, Journal of neurochemistry.
[15] P. Fox,et al. Role of ceruloplasmin in cellular iron uptake. , 1998, Science.
[16] C. Marsden,et al. Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia , 1992 .
[17] J. Poderoso,et al. Nitric oxide, complex I, and the modulation of mitochondrial reactive species in biology and disease. , 2004, Molecular aspects of medicine.
[18] M. Koenig,et al. Friedreich ataxia: the oxidative stress paradox. , 2005, Human molecular genetics.
[19] D. Ben-shachar,et al. The Iron Chelator Desferrioxamine (Desferal) Retards 6‐Hydroxydopamine‐Induced Degeneration of Nigrostriatal Dopamine Neurons , 1991, Journal of neurochemistry.
[20] A Dürr,et al. Clinical and genetic abnormalities in patients with Friedreich's ataxia. , 1996, The New England journal of medicine.
[21] M. Emond,et al. Increased levels of plasma malondialdehyde in Friedreich ataxia. , 2000, Neurology.
[22] Y. Ke,et al. Rethinking the role of ceruloplasmin in brain iron metabolism , 2001, Brain Research Reviews.
[23] A. Rajput,et al. Progressive Supranuclear Palsy , 2001, Drugs & aging.
[24] S. Hayflick. Unraveling the Hallervorden-Spatz syndrome: pantothenate kinase–associated neurodegeneration is the name . . . , 2003, Current opinion in pediatrics.
[25] G. Sawle,et al. Palatal tremor and cognitive decline in neuroferritinopathy , 2002, Journal of neurology, neurosurgery, and psychiatry.
[26] S Cluskey,et al. Mechanisms of neurodegeneration in amyotrophic lateral sclerosis , 2001, Molecular pathology : MP.
[27] Takashi Uehara,et al. Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[28] S. Lipton,et al. Comment on "S-Nitrosylation of Parkin Regulates Ubiquitination and Compromises Parkin's Protective Function" , 2005, Science.
[29] S. Mandel,et al. Gene expression analysis in N‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine mice model of Parkinson's disease using cDNA microarray: effect of R‐apomorphine , 2001, Journal of neurochemistry.
[30] J. Cooper,et al. Clinical, biochemical and molecular genetic correlations in Friedreich's ataxia. , 2000, Human molecular genetics.
[31] B. Carroll,et al. Serum Melanotransferrin, p97 as a Biochemical Marker of Alzheimer's Disease , 2001, Neuropsychopharmacology.
[32] P Trouillas,et al. Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. , 1997, Human molecular genetics.
[33] Katsuhide Ito,et al. Low intensity areas observed on T2-weighted magnetic resonance imaging of the cerebral cortex in various neurological diseases , 1995, Journal of the Neurological Sciences.
[34] J. Connor,et al. Increased incidence of the Hfe mutation in amyotrophic lateral sclerosis and related cellular consequences , 2004, Journal of the Neurological Sciences.
[35] E. Gilbert-Barness,et al. Osmiophilic deposits in cytosomes in Hallervorden-Spatz syndrome. , 1990, Pediatric Neurology.
[36] W. Klein,et al. Iron Levels Modulate α‐Secretase Cleavage of Amyloid Precursor Protein , 1995, Journal of neurochemistry.
[37] M. Gurney,et al. Disease mechanisms revealed by transcription profiling in SOD1‐G93A transgenic mouse spinal cord , 2001, Annals of neurology.
[38] P. Riederer,et al. In Vitro Studies of Ferritin Iron Release and Neurotoxicity , 1998, Journal of neurochemistry.
[39] T. Dawson,et al. Response to Comment on "S-Nitrosylation of Parkin Regulates Ubiquitination and Compromises Parkin's Protective Function" , 2005, Science.
[40] P. Riederer,et al. Iron in brain function and dysfunction with emphasis on Parkinson's disease. , 1991, European neurology.
[41] P. Riederer,et al. Altered Brain Metabolism of Iron as a Cause of Neurodegenerative Diseases? , 1994, Journal of neurochemistry.
[42] T. Montine,et al. Association of HFE mutations with neurodegeneration and oxidative stress in Alzheimer's disease and correlation with APOE , 2003, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[43] H. Miyajima,et al. Familial apoceruloplasmin deficiency associated with blepharospasm and retinal degeneration , 1987, Neurology.
[44] B. Liu,et al. Role of Nitric Oxide in Inflammation‐Mediated Neurodegeneration , 2002, Annals of the New York Academy of Sciences.
[45] Joseph S. Beckman,et al. Widespread Peroxynitrite-Mediated Damage in Alzheimer’s Disease , 1997, The Journal of Neuroscience.
[46] W. D. Ehmann,et al. Aluminum, calcium, and iron in the spinal cord of patients with sporadic amyotrophic lateral sclerosis using laser microprobe mass spectroscopy: a preliminary study , 1995, Journal of the Neurological Sciences.
[47] D. Dressler,et al. Sonographic discrimination of corticobasal degeneration vs progressive supranuclear palsy , 2004, Neurology.
[48] Xudong Huang,et al. An Iron-responsive Element Type II in the 5′-Untranslated Region of the Alzheimer's Amyloid Precursor Protein Transcript* , 2002, The Journal of Biological Chemistry.
[49] T. Rouault,et al. Iron on the brain , 2001, Nature Genetics.
[50] W. Longstreth,et al. Parkinson’s disease risks associated with dietary iron, manganese, and other nutrient intakes , 2003, Neurology.
[51] F. Squitieri,et al. Molecular analysis of juvenile Huntington disease: the major influence on (CAG)n repeat length is the sex of the affected parent. , 1993, Human molecular genetics.
[52] M. Naoi,et al. Apoptosis induced by an endogenous neurotoxin, N-methyl(R)salsolinol, in dopamine neurons. , 2000, Toxicology.
[53] T. Meitinger,et al. An isoform of hPANK2, deficient in pantothenate kinase-associated neurodegeneration, localizes to mitochondria. , 2003, Human molecular genetics.
[54] M. Yorubulut,et al. T2-weighted MRI in Parkinson's disease; substantia nigra pars compacta hypointensity correlates with the clinical scores. , 2004, Neurology India.
[55] Theodore W Randolph,et al. Oxidative dimer formation is the critical rate-limiting step for Parkinson's disease alpha-synuclein fibrillogenesis. , 2003, Biochemistry.
[56] P Z Marmarelis,et al. MRI evaluation of brain iron in earlier- and later-onset Parkinson's disease and normal subjects. , 1999, Magnetic resonance imaging.
[57] P. Blumbergs,et al. Multiple-system atrophy: a new alpha-synuclein disease? , 1998, Lancet.
[58] S. Mandel,et al. Multifunctional Activities of Green Tea Catechins in Neuroprotection , 2005, Neurosignals.
[59] W. D. Ehmann,et al. Copper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimer's disease: possible relation to oxidative stress , 1996, Journal of the Neurological Sciences.
[60] M. Mattson,et al. Role of dietary iron restriction in a mouse model of Parkinson's disease , 2004, Experimental Neurology.
[61] J. Trojanowski,et al. Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies. , 2000, The American journal of pathology.
[62] J. Cooper,et al. Role of Oxidative Damage in Friedreich's Ataxia , 2004, Neurochemical Research.
[63] A. L. Watson,et al. In vitro polymerization of oxidized tau into filaments , 1993, Brain Research.
[64] M. Frasier,et al. Magnesium Inhibits Spontaneous and Iron-induced Aggregation of α-Synuclein* , 2002, The Journal of Biological Chemistry.
[65] J. Trojanowski,et al. Neurodegeneration with Brain Iron Accumulation, Type 1 Is Characterized by α-, β-, and γ-Synuclein Neuropathology , 2000 .
[66] R. Lill,et al. Biogenesis of iron-sulfur proteins in eukaryotes: a novel task of mitochondria that is inherited from bacteria. , 2000, Biochimica et biophysica acta.
[67] J. Kutok,et al. The mitochondrial ATP-binding cassette transporter Abcb7 is essential in mice and participates in cytosolic iron-sulfur cluster biogenesis. , 2006, Human molecular genetics.
[68] H. Feldman,et al. Serum levels of the iron binding protein p97 are elevated in Alzheimer′s disease , 1996, Nature Medicine.
[69] H. Miyajima,et al. Cerebellar ataxia associated with heteroallelic ceruloplasmin gene mutation , 2001, Neurology.
[70] M. Frasier,et al. Magnesium inhibits spontaneous and iron-induced aggregation of alpha-synuclein. , 2002, The Journal of biological chemistry.
[71] Magnetic resonance relaxometry in Parkinson's disease , 2002, Neurological Sciences.
[72] M. Ozeki,et al. A case of clinically and neuropathologically atypical corticobasal degeneration with widespread iron deposition , 2002, Acta Neuropathologica.
[73] Stephen A. Smith,et al. Sea‐blue histiocytes, lymphocytic cytosomes, movement disorder and 59Fe‐uptake in basal ganglia , 1983, Neurology.
[74] C D Marsden,et al. Oxidative DNA Damage in the Parkinsonian Brain: An Apparent Selective Increase in 8‐Hydroxyguanine Levels in Substantia Nigra , 1997, Journal of neurochemistry.
[75] M. Savoiardo. Differential diagnosis of Parkinson's disease and atypical parkinsonian disorders by magnetic resonance imaging , 2003, Neurological Sciences.
[76] S. Przedborski,et al. Oxidative Stress in Parkinson's Disease , 2008, Annals of the New York Academy of Sciences.
[77] M. Naoi,et al. Mitochondria determine the survival and death in apoptosis by an endogenous neurotoxin, N-methyl(R)salsolinol, and neuroprotection by propargylamines , 2002, Journal of Neural Transmission.
[78] P. Harrison,et al. The ferritins: molecular properties, iron storage function and cellular regulation. , 1996, Biochimica et biophysica acta.
[79] F. Foury. Low iron concentration and aconitase deficiency in a yeast frataxin homologue deficient strain , 1999, FEBS letters.
[80] A. Coulthard,et al. Neuroferritinopathy in a French family with late onset dominant dystonia , 2003, Journal of medical genetics.
[81] A. Koeppen,et al. Iron in the Hallervorden-Spatz syndrome. , 2001, Pediatric neurology.
[82] E. Stadtman,et al. Protein Oxidation in Aging and Age‐Related Diseases , 2001, Annals of the New York Academy of Sciences.
[83] T. Fujiwara,et al. Cloning and chromosomal mapping of a novel ABC transporter gene (hABC7), a candidate for X-linked sideroblastic anemia with spinocerebellar ataxia , 1998, Journal of Human Genetics.
[84] M. Youdim,et al. Ironing Iron Out in Parkinson's Disease and Other Neurodegenerative Diseases with Iron Chelators: A Lesson from 6‐Hydroxydopamine and Iron Chelators, Desferal and VK‐28 , 2004, Annals of the New York Academy of Sciences.
[85] J. Gitlin,et al. Aceruloplasminemia: an inherited neurodegenerative disease with impairment of iron homeostasis. , 1998, The American journal of clinical nutrition.
[86] M. Smith,et al. Is increased redox-active iron in Alzheimer disease a failure of the copper-binding protein ceruloplasmin? , 1999, Free radical biology & medicine.
[87] Mark Hallett,et al. Increased iron in the dentate nucleus of patients with Friedreich's ataxia , 1999, Annals of neurology.
[88] J. Connor,et al. Iron regulation in the brain: Histochemical, biochemical, and molecular considerations , 1992, Annals of neurology.
[89] V. Seshadri,et al. Ceruloplasmin Ferroxidase Activity Stimulates Cellular Iron Uptake by a Trivalent Cation-specific Transport Mechanism* , 1999, The Journal of Biological Chemistry.
[90] M. Zigmond,et al. Supersensitivity after intraventricular 6-hydroxydopamine: Relation to dopamine depletion , 1980, Experientia.
[91] G. Perry,et al. Oxidative Stress and Redox‐Active Iron in Alzheimer's Disease , 2004, Annals of the New York Academy of Sciences.
[92] G. Rotilio,et al. Neurodegeneration in amyotrophic lateral sclerosis: the role of oxidative stress and altered homeostasis of metals , 2003, Brain Research Bulletin.
[93] Y. Agid,et al. Association study between iron-related genes polymorphisms and Parkinson's disease , 2002, Journal of Neurology.
[94] Subramanian Rajagopalan,et al. Genetic or Pharmacological Iron Chelation Prevents MPTP-Induced Neurotoxicity In Vivo A Novel Therapy for Parkinson's Disease , 2003, Neuron.
[95] T. Montine,et al. Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. , 2004, Chemistry and physics of lipids.
[96] R. Lill,et al. An interaction between frataxin and Isu1/Nfs1 that is crucial for Fe/S cluster synthesis on Isu1 , 2003, EMBO reports.
[97] Gary Fiskum,et al. Generation of reactive oxygen species by the mitochondrial electron transport chain , 2002, Journal of neurochemistry.
[98] J. Cooper,et al. Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease , 1998, Annals of neurology.
[99] J. Parisi,et al. Depletion of catecholaminergic neurons of the rostral ventrolateral medulla in multiple systems atrophy with autonomic failure , 1998, Annals of neurology.
[100] G. Bartzokis,et al. Increased basal ganglia iron levels in Huntington disease. , 1999, Archives of neurology.
[101] M. MacDonald,et al. Huntingtin: an iron-regulated protein essential for normal nuclear and perinuclear organelles. , 2000, Human molecular genetics.
[102] L. Marnett,et al. Oxyradicals and DNA damage. , 2000, Carcinogenesis.
[103] R. Garruto,et al. Concentrations of zinc and iron in the brains of Guamanian patients with amyotrophic lateral sclerosis and parkinsonism-dementia. , 1993, Neurotoxicology.
[104] J. Delgado-García,et al. Brain Damage and Repair , 2004, Springer Netherlands.
[105] D. Berg,et al. In vivo detection of iron and neuromelanin by transcranial sonography – a new approach for early detection of substantia nigra damage , 2006, Journal of Neural Transmission.
[106] Bertram Müller-Myhsok,et al. Mutations in the pantothenate kinase gene PANK2 are not associated with Parkinson disease , 2005, Neuroscience Letters.
[107] J. Trojanowski,et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. , 2000, Science.
[108] Mark A. Smith,et al. 4‐Hydroxynonenal‐Derived Advanced Lipid Peroxidation End Products Are Increased in Alzheimer's Disease , 1997, Journal of neurochemistry.
[109] K. Swaiman. Hallervorden-Spatz syndrome. , 1990, Pediatric neurology.
[110] M. Youdim,et al. Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats , 2004, Neuropharmacology.
[111] Y. Kagawa,et al. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. , 1989, Biochemical and biophysical research communications.
[112] H. Miyajima,et al. Aceruloplasminemia with a novel mutation associated with parkinsonism , 2000, Neurogenetics.
[113] M. Youdim,et al. Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases. , 2005, Bioorganic & medicinal chemistry.
[114] J. Bart,et al. Blood–brain barrier dysfunction in parkinsonian midbrain in vivo , 2005, Annals of neurology.
[115] J. Valpuesta,et al. Ferritin is associated with the aberrant tau filaments present in progressive supranuclear palsy. , 1998, The American journal of pathology.
[116] A. Friedman,et al. Controversies about iron in parkinsonian and control substantia nigra. , 1997, Acta neurobiologiae experimentalis.
[117] G. Reynolds,et al. Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain , 2005, Journal of Neural Transmission.
[118] M. Gerlach,et al. Formation of Radicals , 2004 .
[119] P. Kidd,et al. Parkinson's disease as multifactorial oxidative neurodegeneration: implications for integrative management. , 2000, Alternative medicine review : a journal of clinical therapeutic.
[120] Elizabeth C. Theil. Ferritin: structure, gene regulation, and cellular function in animals, plants, and microorganisms. , 1987, Annual review of biochemistry.
[121] J. Salamone,et al. Characterization of the impaired feeding behavior in rats given haloperidol or dopamine-depleting brain lesions , 1990, Neuroscience.
[122] M. Youdim,et al. Novel multifunctional neuroprotective iron chelator‐monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition , 2005, Journal of neurochemistry.
[123] K. Tipton,et al. Mechanism of inhibition of mitochondrial respiratory complex I by 6-hydroxydopamine and its prevention by desferrioxamine. , 1998, European Journal of Pharmacology.
[124] K. Ohtomo,et al. Amyotrophic lateral sclerosis: T2 shortening in motor cortex at MR imaging. , 1993, Radiology.
[125] P. Hof,et al. The iron-binding protein lactotransferrin is present in pathologic lesions in a variety of neurodegenerative disorders: a comparative immunohistochemical analysis , 1994, Brain Research.
[126] M. Youdim,et al. The potential role of iron chelators in the treatment of Parkinson's disease and related neurological disorders. , 1997, Pharmacology & toxicology.
[127] M. Pandolfo,et al. Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin. , 1997, Science.
[128] J. Connor,et al. Abnormal localization of iron regulatory protein in Alzheimer's disease , 1998, Brain Research.
[129] K. Marder,et al. Dietary iron, animal fats, and risk of Parkinson's disease. , 1998, Movement disorders : official journal of the Movement Disorder Society.
[130] S. Murayama,et al. Lewy body in neurodegeneration with brain iron accumulation type 1 is immunoreactive for α-synuclein , 1998, Neurology.
[131] J. Gitlin,et al. Targeted gene disruption reveals an essential role for ceruloplasmin in cellular iron efflux. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[132] B. Lemieux,et al. The Cardiomyopathy of Friedreich's Ataxia Morphological Observations in 3 Cases , 1980, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[133] H. Miyajima,et al. Molecular and pathological basis of aceruloplasminemia. , 2006, Biological research.
[134] W. Neupert,et al. The mitochondrial proteins Ssq1 and Jac1 are required for the assembly of iron sulfur clusters in mitochondria. , 2001, Journal of molecular biology.
[135] H. Reichmann,et al. Mitochondrial dysfunction – a pathogenetic factor in Parkinson’s disease , 2000, Journal of Neurology.
[136] S. Mandel,et al. The Pivotal Role of Iron in NF‐κB Activation and Nigrostriatal Dopaminergic Neurodegeneration: Prospects for Neuroprotection in Parkinson's Disease with Iron Chelators , 1999, Annals of the New York Academy of Sciences.
[137] Mark A. Wilson,et al. The oxidation state of DJ-1 regulates its chaperone activity toward α-synuclein , 2006 .
[138] O. Hardiman,et al. Association of the H63D polymorphism in the hemochromatosis gene with sporadic ALS , 2005, Neurology.
[139] J. Sarsero,et al. Friedreich's Ataxia, No Changes in Mitochondrial Labile Iron in Human Lymphoblasts and Fibroblasts , 2005, Journal of Biological Chemistry.
[140] G Becker,et al. Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography , 1995, Neurology.
[141] C. Morris,et al. Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease , 2001, Nature Genetics.
[142] H. Miyajima,et al. Aceruloplasminemia, an inherited disorder of iron metabolism , 2003, Biometals.
[143] G. Petsko,et al. The oxidation state of DJ-1 regulates its chaperone activity toward alpha-synuclein. , 2006, Journal of molecular biology.
[144] Makoto Hashimoto,et al. Human recombinant NACP/α-synuclein is aggregated and fibrillated in vitro: Relevance for Lewy body disease , 1998, Brain Research.
[145] O. Rascol,et al. Hereditary ferritinopathy , 2003, Journal of the Neurological Sciences.
[146] R. Brooks,et al. T1 and T2 in the brain of healthy subjects, patients with Parkinson disease, and patients with multiple system atrophy: relation to iron content. , 1999, Radiology.
[147] G. Arendash,et al. Time-dependent changes in iron levels and associated neuronal loss within the substantia nigra following lesions within the neostriatum/globus pallidus complex , 1995, Neuroscience.
[148] T. Dawson,et al. Molecular Pathways of Neurodegeneration in Parkinson's Disease , 2003, Science.
[149] Allan I. Levey,et al. Oxidative Modifications and Down-regulation of Ubiquitin Carboxyl-terminal Hydrolase L1 Associated with Idiopathic Parkinson's and Alzheimer's Diseases* , 2004, Journal of Biological Chemistry.
[150] D. Dickson,et al. Multiple System Atrophy: A Sporadic Synucleinopathy , 1999, Brain pathology.
[151] D. Butterfield,et al. Free radicals and brain aging. , 2004, Clinics in geriatric medicine.
[152] R. Krüger,et al. The FASEB Journal express article 10.1096/fj.04-3486fje. Published online September 8, 2005. Functional relevance of ceruloplasmin mutations in Parkinson’s Disease , 2022 .
[153] T. Taylor,et al. Homozygosity mapping of Hallervorden–Spatz syndrome to chromosome 20p12.3–p13 , 1996, Nature Genetics.
[154] A. Hutchinson,et al. Mutation of a Putative Mitochondrial Iron Transporter Gene (ABC7) in X-Linked Sideroblastic Anemia and Ataxia (XLSA/A) , 1999, Human molecular genetics.
[155] R. Lill,et al. Identification of a human mitochondrial ABC transporter, the functional orthologue of yeast Atm1p , 1998, FEBS letters.
[156] C. Higgins,et al. ABC transporters: from microorganisms to man. , 1992, Annual review of cell biology.
[157] E. Hatchwell,et al. X-linked sideroblastic anaemia with ataxia: another mitochondrial disease? , 2001, Journal of neurology, neurosurgery, and psychiatry.
[158] S. Mandel,et al. Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes , 2004, Journal of Neural Transmission.
[159] G. Bartzokis,et al. In vivo evaluation of brain iron in Alzheimer disease using magnetic resonance imaging. , 2000, Archives of general psychiatry.
[160] E. Stopa,et al. Neural Heme Oxygenase-1 Expression in Idiopathic Parkinson's Disease , 1998, Experimental Neurology.
[161] H. Shibasaki,et al. Oxidative stress causes abnormal accumulation of familial amyotrophic lateral sclerosis-related mutant SOD1 in transgenic Caenorhabditis elegans. , 2001, Human molecular genetics.
[162] N P Quinn,et al. Clinicopathological study of 35 cases of multiple system atrophy. , 1995, Journal of neurology, neurosurgery, and psychiatry.
[163] J. Gitlin,et al. Biochemical Analysis of a Missense Mutation in Aceruloplasminemia* , 2002, The Journal of Biological Chemistry.
[164] Alberto Gatti,et al. The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[165] S. Gallati,et al. Neuroferritinopathy: Missense mutation in FTL causing early-onset bilateral pallidal involvement , 2005, Neurology.
[166] S. Aust,et al. Stimulation of the ferroxidase activity of ceruloplasmin during iron loading into ferritin. , 1997, Archives of biochemistry and biophysics.
[167] H U Rehman,et al. Multiple system atrophy , 2001, Postgraduate medical journal.
[168] E. Dooling,et al. Hallervorden-Spatz syndrome. , 1974, Archives of neurology.
[169] P. Ponka. Hereditary Causes of Disturbed Iron Homeostasis in the Central Nervous System , 2004, Annals of the New York Academy of Sciences.
[170] K F Swaiman,et al. Hallervorden-Spatz syndrome and brain iron metabolism. , 1991, Archives of neurology.
[171] J. Trojanowski,et al. Altered Neuronal Mitochondrial Coenzyme A Synthesis in Neurodegeneration with Brain Iron Accumulation Caused by Abnormal Processing, Stability, and Catalytic Activity of Mutant Pantothenate Kinase 2 , 2005, The Journal of Neuroscience.
[172] James R. Connor,et al. Brain iron uptake and homeostatic mechanisms: An overview , 2003, Biometals.
[173] R. Lill,et al. The mitochondrial proteins Atm1p and Nfs1p are essential for biogenesis of cytosolic Fe/S proteins , 1999, The EMBO journal.
[174] T. Bird,et al. Hereditary sideroblastic anaemia and ataxia: an X linked recessive disorder. , 1985, Journal of medical genetics.
[175] W. D. Ehmann,et al. Imbalances of trace elements related to oxidative damage in Alzheimer's disease brain. , 1998, Neurotoxicology.
[176] C. C. Johnson,et al. Adult nutrient intake as a risk factor for Parkinson's disease. , 1999, International journal of epidemiology.
[177] W. Halliday,et al. Hallervorden-Spatz disease: MR and pathologic findings. , 1993, AJNR. American journal of neuroradiology.
[178] T. Hirokawa,et al. Alterations of structure and hydrolase activity of parkinsonism-associated human ubiquitin carboxyl-terminal hydrolase L1 variants. , 2003, Biochemical and biophysical research communications.
[179] M. Youdim,et al. Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine. , 1995, European journal of pharmacology.
[180] Ashley I. Bush,et al. Redox-active iron mediates amyloid-β toxicity , 2001 .
[181] C. Crosio,et al. Superoxide dismutase 1 modulates expression of transferrin receptor , 2006, JBIC Journal of Biological Inorganic Chemistry.
[182] J. Tolmie,et al. Human ABC7 transporter: gene structure and mutation causing X-linked sideroblastic anemia with ataxia with disruption of cytosolic iron-sulfur protein maturation. , 2000, Blood.
[183] R I Grossman,et al. Magnetic resonance imaging in Parkinson's disease and parkinsonian syndromes , 1989, Neurology.
[184] C. Quintana,et al. Study of the localization of iron, ferritin, and hemosiderin in Alzheimer's disease hippocampus by analytical microscopy at the subcellular level. , 2006, Journal of structural biology.
[185] P. Arosio,et al. Neuroferritinopathy: a neurodegenerative disorder associated with L-ferritin mutation. , 2005, Best practice & research. Clinical haematology.
[186] J. Sung,et al. PATHOLOGY OF SHY‐DRAGER SYNDROME* , 1978, Journal of neuropathology and experimental neurology.
[187] Shawn K. Westaway,et al. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome , 2001, Nature Genetics.
[188] P. Bauer,et al. Ceruloplasmin gene variations and substantia nigra hyperechogenicity in Parkinson disease , 2004, Neurology.
[189] J. Witztum,et al. Abnormal Iron Deposition Associated With Lipid Peroxidation in Transgenic Mice Expressing lnterleukin-6 in the Brain , 1998, Journal of neuropathology and experimental neurology.
[190] C. Batich,et al. In situ characterization and mapping of iron compounds in Alzheimer's disease tissue. , 2005, Journal of Alzheimer's disease : JAD.
[191] S. Mandel,et al. cDNA gene expression profile homology of antioxidants and their antiapoptotic and proapoptotic activities in human neuroblastoma cells , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[192] Rabi Tawil,et al. Hereditary ferritinopathy: a novel mutation, its cellular pathology, and pathogenetic insights. , 2005, Journal of neuropathology and experimental neurology.
[193] J. Gitlin,et al. Expression of the ceruloplasmin gene in the human retina and brain: implications for a pathogenic model in aceruloplasminemia. , 1996, Human molecular genetics.
[194] Sun-Young Lee,et al. Lipid interaction of α‐synuclein during the metal‐catalyzed oxidation in the presence of Cu2+ and H2O2 , 2003, Journal of neurochemistry.
[195] Peter Riederer,et al. Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains , 1989, Journal of neurochemistry.
[196] R. Benecke,et al. Substantia nigra echogenicity is normal in non-extrapyramidal cerebral disorders but increased in Parkinson's disease , 2002, Journal of Neural Transmission.
[197] M. Youdim,et al. Novel multifunctional neuroprotective iron chelator‐monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP‐induced striatal dopamine depletion , 2005, Journal of neurochemistry.
[198] Ya Ke,et al. Iron misregulation in the brain: a primary cause of neurodegenerative disorders , 2003, The Lancet Neurology.
[199] T. Montine,et al. Hydroxynonenal adducts indicate a role for lipid peroxidation in neocortical and brainstem Lewy bodies in humans , 2002, Neuroscience Letters.
[200] C. Glabe,et al. Binding of Zn(II), Cu(II), and Fe(II) ions to Alzheimer's A beta peptide studied by fluorescence. , 1999, Bioorganic & medicinal chemistry letters.
[201] Sri Nabawiyati nurul Makiyah. Cell Signaling Pathways in the Neuroprotective Actions of the Green Tea Polyphenol (-)-epigallocatechin-3-gallate: Implications for Neurodegenerative Diseases , 2005 .
[202] D. Praticò. In vivo measurement of the redox state , 2001, Lipids.
[203] M. Smith,et al. Redox-active iron mediates amyloid-beta toxicity. , 2001, Free radical biology & medicine.
[204] C. Marsden,et al. Decreased Ferritin Levels in Brain in Parkinson's Disease , 1990, Journal of neurochemistry.
[205] C. Marsden,et al. Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease , 1989, Journal of neurochemistry.
[206] Y. Wada,et al. Hereditary ceruloplasmin deficiency with hemosiderosis , 1996, Human Genetics.
[207] C. C. Johnson,et al. Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson's disease. , 1999, Neurotoxicology.
[208] G. Bartzokis,et al. MRI evaluation of basal ganglia ferritin iron and neurotoxicity in Alzheimer's and Huntingon's disease. , 2000, Cellular and molecular biology.
[209] J. Connor,et al. Iron, brain ageing and neurodegenerative disorders , 2004, Nature Reviews Neuroscience.
[210] R M Henkelman,et al. MR of human postmortem brain tissue: correlative study between T2 and assays of iron and ferritin in Parkinson and Huntington disease. , 1993, AJNR. American journal of neuroradiology.
[211] O. Rascol,et al. Intracellular Ferritin Accumulation in Neural and Extraneural Tissue Characterizes a Neurodegenerative Disease Associated with a Mutation in the Ferritin Light Polypeptide Gene , 2004, Journal of neuropathology and experimental neurology.
[212] G. Brittenham,et al. Role of iron in NF-kappa B activation and cytokine gene expression by rat hepatic macrophages. , 1997, The American journal of physiology.
[213] G. C. Ferreira,et al. Mitochondrial iron detoxification is a primary function of frataxin that limits oxidative damage and preserves cell longevity. , 2006, Human molecular genetics.
[214] N P Quinn,et al. Olivopontocerebellar pathology in multiple system atrophy , 1996, Movement disorders : official journal of the Movement Disorder Society.
[215] A. Abeliovich,et al. DJ-1 Is a Redox-Dependent Molecular Chaperone That Inhibits α-Synuclein Aggregate Formation , 2004, PLoS biology.
[216] K. Tipton,et al. Nature of Inhibition of Mitochondrial Respiratory Complex I by 6‐Hydroxydopamine , 1996, Journal of neurochemistry.
[217] G Becker,et al. Iron accumulation in the substantia nigra in rats visualized by ultrasound. , 1999, Ultrasound in medicine & biology.
[218] Ken-ichi Isobe,et al. An inhibitor of mitochondrial complex I, rotenone, inactivates proteasome by oxidative modification and induces aggregation of oxidized proteins in SH‐SY5Y cells , 2003, Journal of neuroscience research.
[219] M. Prieto-Carrasquero,et al. 'In vivo diagnosis of Hallervorden-Spatz disease'. , 1996, Developmental medicine and child neurology.
[220] P. Riederer,et al. Crosslinking of α-synuclein by advanced glycation endproducts — an early pathophysiological step in Lewy body formation? , 2000, Journal of Chemical Neuroanatomy.
[221] D. Richardson,et al. Frataxin: its role in iron metabolism and the pathogenesis of Friedreich's ataxia. , 2001, The international journal of biochemistry & cell biology.
[222] R. Allikmets,et al. Evolution of ATP-binding cassette transporter genes. , 1995, Current opinion in genetics & development.
[223] M. Youdim,et al. Iron involvement in neural damage and microgliosis in models of neurodegenerative diseases. , 2000, Cellular and molecular biology.
[224] J. Connor,et al. A histochemical study of iron, transferrin, and ferritin in Alzheimer's diseased brains , 1992, Journal of neuroscience research.
[225] M. Vérin,et al. Aceruloplasminemia: new clinical, pathophysiological and therapeutic insights. , 2002, Journal of hepatology.
[226] S. Fahn,et al. Study of movement disorders and brain iron by MR. , 1987, AJR. American journal of roentgenology.
[227] E. Ciceri,et al. Magnetic resonance imaging in progressive supranuclear palsy and other parkinsonian disorders. , 1994, Journal of neural transmission. Supplementum.
[228] M Hutchinson,et al. Structural changes of the substantia nigra in Parkinson's disease as revealed by MR imaging. , 2000, AJNR. American journal of neuroradiology.
[229] A. Nakamura,et al. Increased lipid peroxidation in the brains of aceruloplasminemia patients , 2000, Journal of the Neurological Sciences.
[230] C. Rock,et al. Cloning and Characterization of a Eukaryotic Pantothenate Kinase Gene (panK) from Aspergillus nidulans * , 1999, The Journal of Biological Chemistry.
[231] T. Siddique,et al. Current status of SOD1 mutations in familial amyotrophic lateral sclerosis. , 2000, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.
[232] Daniela Berg,et al. Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. , 2002, Archives of neurology.
[233] P. Mantyh,et al. Aluminum, Iron, and Zinc Ions Promote Aggregation of Physiological Concentrations of β‐Amyloid Peptide , 1993, Journal of neurochemistry.
[234] Irene Litvan,et al. Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia , 2003, Annals of neurology.
[235] F. Ye,et al. Increased Basal Ganglia Iron in Striatonigral Degeneration: In Vivo Estimation with Magnetic Resonance , 1998, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[236] D. Radisky,et al. The Yeast Frataxin Homologue Mediates Mitochondrial Iron Efflux , 1999, The Journal of Biological Chemistry.
[237] A. Munnich,et al. Aconitase and mitochondrial iron–sulphur protein deficiency in Friedreich ataxia , 1997, Nature Genetics.
[238] Robert B. Wilson,et al. Increased IRP1 activity in Friedreich ataxia. , 2005, Gene.
[239] W. Jefferies,et al. Reactive microglia specifically associated with amyloid plaques in Alzheimer's disease brain tissue express melanotransferrin , 1996, Brain Research.
[240] G M SHY,et al. A neurological syndrome associated with orthostatic hypotension: a clinical-pathologic study. , 1960, Archives of neurology.
[241] D. Loeffler,et al. Ceruloplasmin immunoreactivity in neurodegenerative disorders , 2001, Free radical research.
[242] P. Lantos,et al. Office of Rare Diseases Neuropathologic Criteria for Corticobasal Degeneration , 2002, Journal of neuropathology and experimental neurology.
[243] J. Connor,et al. Regional distribution of iron and iron‐regulatory proteins in the brain in aging and Alzheimer's disease , 1992, Journal of neuroscience research.
[244] P. Blumbergs,et al. Multiple-system atrophy: a new α-synuclein disease? , 1998, The Lancet.
[245] J. Jankovic,et al. Clinical heterogeneity of neurodegeneration with brain iron accumulation (Hallervorden‐Spatz syndrome) and pantothenate kinase‐associated neurodegeneration , 2004, Movement disorders : official journal of the Movement Disorder Society.